基于术前MRI与临床特征的多中心肝内肿块型胆管癌诊断系统
多中心回顾性纳入1008例患者(504例病理确诊IMCC及成比例HCC和cHCC-CC),通过决策树分析建立基于临床和MRI特征的无创诊断系统,内部训练、内部测试和外部验证AUC分别为0.971、0.956、0.945,≤3 cm小病灶AUC为0.956。
要点
- 增强模式在诊断系统中权重最高(0.816),分叶状形态、靶样表现、肝表面回缩等MRI征象有助于鉴别IMCC。
- 该系统在外部验证队列AUC达0.945,≤3 cm小病灶AUC达0.956,对日常鉴别诊断有参考价值。
- 女性、无慢性肝病或肝硬化、CA19-9升高、AFP正常等临床特征为IMCC的独立预测因素。
核心结论
- 该决策树诊断系统在多中心数据中表现出良好泛化能力和临床效能,可能作为无创、可靠、易操作的工具用于IMCC诊断,帮助区分IMCC与其他含HCC的原发性肝癌。
研究设计与样本
- 多中心回顾性研究,纳入1008例患者,其中病理确诊IMCC 504例及成比例的肝细胞癌(HCC)和混合型肝细胞-胆管细胞癌(cHCC-CC),内部队列700例、外部队列308例,基于术前MRI和临床特征建立决策树诊断系统。
关键影像表现/征象
- 分叶状肿瘤形态为支持IMCC的独立MRI特征。
- 渐进性或持续性强化模式为支持IMCC的独立MRI特征,权重最高(0.816)。
- 无强化肿瘤包膜为支持IMCC的独立MRI特征。
- 靶样表现为支持IMCC的独立MRI特征。
- 肝表面回缩为支持IMCC的独立MRI特征。
诊断标准与关键数值
- 女性、无慢性肝病或肝硬化、CA19-9升高、AFP正常为支持IMCC的独立临床特征(比值比=3.273–25.00,p<0.001至p=0.021)。
- 诊断系统内部训练队列AUC 0.971,内部测试队列AUC 0.956,外部验证队列AUC 0.945。
- ≤3 cm小病灶中诊断系统AUC 0.956。
临床应用与阅片要点
- 作者认为该诊断系统可能作为无创、易操作、可解释的工具用于IMCC诊断和风险分层。
- 作者认为该系统在考虑多中心良好泛化能力和临床效能的情况下,可能为临床决策提供重要信息。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To establish a non-invasive diagnostic system for intrahepatic mass-forming cholangiocarcinoma (IMCC) via decision tree analysis.
METHODS: Totally 1008 patients with 504 pathologically confirmed IMCCs and proportional hepatocellular carcinomas (HCC) and combined hepatocellular cholangiocarcinomas (cHCC-CC) from multi-centers were retrospectively included (internal cohort n = 700, external cohort n = 308). Univariate and multivariate logistic regression analyses were applied to evaluate the independent clinical and MRI predictors for IMCC, and the selected features were used to develop a decision tree-based diagnostic system. Diagnostic efficacy of the established system was calculated by the receiver operating characteristic curve analysis in the internal training-testing and external validation cohorts, and also in small lesions ≤ 3 cm.
RESULTS: Multivariate analysis revealed that female, no chronic liver disease or cirrhosis, elevated carbohydrate antigen 19-9 (CA19-9) level, normal alpha-fetoprotein (AFP) level, lobulated tumor shape, progressive or persistent enhancement pattern, no enhancing tumor capsule, targetoid appearance, and liver surface retraction were independent characteristics favoring the diagnosis of IMCC over HCC or cHCC-CC (odds ratio = 3.273-25.00, p < 0.001 to p = 0.021). Among which enhancement pattern had the highest weight of 0.816. The diagnostic system incorporating significant characteristics above showed excellent performance in the internal training (area under the curve (AUC) 0.971), internal testing (AUC 0.956), and external validation (AUC 0.945) cohorts, as well as in small lesions ≤ 3 cm (AUC 0.956).
CONCLUSIONS: In consideration of the great generalizability and clinical efficacy in multi-centers, the proposed diagnostic system may serve as a non-invasive, reliable, and easy-to-operate tool in IMCC diagnosis, providing an efficient approach to discriminate IMCC from other HCC-containing primary liver cancers.
CLINICAL RELEVANCE STATEMENT: This study established a non-invasive, easy-to-operate, and explainable decision tree-based diagnostic system for intrahepatic mass-forming cholangiocarcinoma, which may provide essential information for clinical decision-making.
KEY POINTS: • Distinguishing intrahepatic mass-forming cholangiocarcinoma (IMCC) from other primary liver cancers is important for both treatment planning and outcome prediction. • The MRI-based diagnostic system showed great performance with satisfying generalization ability in the diagnosis and discrimination of IMCC. • The diagnostic system may serve as a non-invasive, easy-to-operate, and explainable tool in the diagnosis and risk stratification for IMCC.
引用
- Sheng R, Zhang Y, Wang H, et al. A multi-center diagnostic system for intrahepatic mass-forming cholangiocarcinoma based on preoperative MRI and clinical features. Eur Radiol. 2023. PMID: 37552257. doi:10.1007/s00330-023-10002-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。